Isofol Medical AB (publ) appoints Carnegie Investment Bank AB (publ) to Financial advisor

GOTHENBURG, Sweden, February 27, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), announced today that the company and the board have appointed Carnegie Investment Bank AB (publ) as financial advisor to explore a possible listing of the company’s shares at Nasdaq Stockholm main market within 12-18 months and to evaluate other strategic and financial initiatives together with Pareto Securities AB.

For further information, please contact:

Isofol Medical AB (publ)
Anders Rabbe, CEO
E­-mail: info@isofolmedical.com
Phone: +46 (0)707 646 500

Gustaf Albert, CFO
E­-mail: gustaf.albert@isofolmedical.com
Phone: +46 (0)709 168 302

Certified Adviser
FNCA Sweden AB
E-mail: info@fnca.se
Phone: +46 (0)8 528 003 99

About arfolitixorin

Arfolitixorin is Isofol’s proprietary drug candidate being developed to increase the efficacy of standard of care chemotherapy for advanced colorectal cancer. The drug candidate is currently being studied in a global Phase 3 clinical trial. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.

About Isofol Medical AB (publ)

Isofol Medical AB (publ) is a clinical stage biotech company developing arfolitixorin to improve the efficacy of standard of care chemotherapy for advanced colorectal cancer by increasing tumor response and progression free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB is traded on the Nasdaq First North Premier. Certified Adviser is FNCA Sweden AB.

www.isofolmedical.com

Release
Scroll to Top